<DOC>
	<DOCNO>NCT01726868</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety blood purification therapy renal dysfunction cholesterol crystal embolism .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Blood Purification Therapy Cholesterol Crystal Embolism</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Embolism , Cholesterol</mesh_term>
	<criteria>Patients meet following criterion . Patients cardiac catheterization vascular surgery last 24 week time obtain informed consent . Patients satisfy follow criterion diagnose CCE skin renal biopsy . 1 . Patients progressive renal dysfunction course week month . 2 . Patients skin lesion livedo reticularis low extremity blue toe syndrome . 3 . Eosinophil count 400 per microliter . Patients patient whose legal representative understood requirement study sign informed consent form . Patients meet follow criterion exclude . Patients contraindication anticoagulant ( Nafamostat Mesilate ) . Blood purification therapy inapplicable severe heart failure , acute myocardial infarction , severe arrhythmia , acute stroke , severe uncontrollable hypertension hypotension . Patients body weight less 40kg . Patients history allergic reaction hypersensitivity blood purification . Patients stop take ACE inhibitor . Patients disease corticosteroid , statin contraindicate . Patients participate another clinical trial study time obtain informed consent . Patients receive chronic hemodialysis . Otherwise , patient judge investigator unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>